| Literature DB >> 26206262 |
Damien Lhenry1, Manuel Larrouy1, Claire Bernhard1, Victor Goncalves1, Olivier Raguin2, Peggy Provent2, Mathieu Moreau1, Bertrand Collin1,3, Alexandra Oudot3, Jean-Marc Vrigneaud3, François Brunotte3, Christine Goze4, Franck Denat5.
Abstract
In molecular imaging, multimodal imaging agents can provide complementary information, for improving the accuracy of disease diagnosis or enhancing patient management. In particular, optical/nuclear imaging may find important preclinical and clinical applications. To simplify the preparation of dual-labeled imaging agents, we prepared versatile monomolecular multimodal imaging probe (MOMIP) platforms containing both a fluorescent dye (BODIPY) and a metal chelator (polyazamacrocycle). One of the MOMIP was conjugated to a cyclopeptide (i.e., octreotide) and radiolabeled with (111) In. In vitro and in vivo studies of the resulting bioconjugate were conducted, highlighting the potential of these BODIPY-based bimodal probes. This work also confirmed that the biovector and/or the bimodal probes must be chosen carefully, due to the impact of the MOMIP on the overall properties of the resulting imaging agent.Entities:
Keywords: BODIPY; imaging agents; macrocycles; molecular imaging; optical imaging; positron emission tomography
Year: 2015 PMID: 26206262 DOI: 10.1002/chem.201501676
Source DB: PubMed Journal: Chemistry ISSN: 0947-6539 Impact factor: 5.236